Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. - Wikidata - awgldk - TriplyDB

Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.

Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.

http://www.wikidata.org/entity/Q34950386

about

BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscle Implantable Devices for Sustained, Intravesical Drug Delivery Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes.Bladder sensory desensitization decreases urinary urgency.A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.Development of evidence-based Australian medication-related indicators of potentially preventable hospitalisations: a modified RAND appropriateness method Oxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian women Medical management of overactive bladder Efficacy and safety of Baweidihuang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trial Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.Muscarinic receptors in the bladder: from basic research to therapeutics.Anti-diuresis in the management of daytime urinary -incontinence.An overview of the clinical use of antimuscarinics in the treatment of overactive bladder Bladder dysfunction in diabetes mellitus.Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence Adipose derived stem cells ameliorate hyperlipidemia associated detrusor overactivity in a rat model Purinoceptors as therapeutic targets for lower urinary tract dysfunction.Cocaine- and amphetamine-regulated transcript peptide (CARTp): distribution and function in rat urinary bladder.Effects of a Gentle, Self-Administered Stimulation of Perineal Skin for Nocturia in Elderly Women: A Randomized, Placebo-Controlled, Double-Blind Crossover Trial.Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis.Role of muscarinic receptor antagonists in urgency and nocturia.Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus.The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.Experience with imidafenacin in the management of overactive bladder disorder Developments in pharmacological therapy for the overactive bladder.The challenge of overactive bladder therapy: alternative to antimuscarinic agents.New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Chiropractic care of interstitial cystitis/painful bladder syndrome associated with pelvic lumbar spine dysfunction: a case series Pharmacologic management of overactive bladder.Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.Regenerative medicine based applications to combat stress urinary incontinence.Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment.The medical treatment of overactive bladder, including current and future treatments.Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults.

P2860

Q24642564-58F1A132-3543-401E-A67A-BDB6578F1CBD Q26744682-DDDD6F85-89F8-451B-99FD-5650B6BE305E Q28742444-A68B7F10-9AA8-4C74-8800-8A2809F75874 Q30483622-66B38DF0-5E73-4722-A912-BE37842EEA27 Q30832054-382868DF-92C5-4BF1-B6A6-ECA7FDAF10D7 Q33485538-2D0BD116-E286-4D26-979B-4C0676E538CB Q33569589-DCBDA7C6-F3D9-4E3C-AFD4-14B8FD6A3DA3 Q33783024-EFA398D8-F7EB-4A45-A274-DC3BA47E2DFE Q34124065-CF709EFB-2362-4252-A98C-6E52E027CBEE Q34415046-ECF99CE4-8D8A-432B-BEDB-3517723A893C Q34543969-6468AA2F-A239-4E91-BA10-3B163260C32F Q34564708-05318416-3506-4955-A7CD-3C2F64BFC15F Q34608213-3C90DBC1-A937-4BF3-B153-F4F563411C6E Q35042575-EE5C4B80-04A4-45AD-A853-C5BE44FEF7B1 Q35155238-8282C4C1-CB42-46CC-AF4A-94C0297FE145 Q35166683-684F9B6F-7EFA-4A5D-8058-8F42ADF7192F Q35185998-ED6BCCAD-CD54-46F8-A229-002A587D7877 Q35545723-67D36754-B56D-47F5-BA01-02A10F6F2F5E Q35679793-C412FCDC-4F13-4805-B45A-095FB3DB48D8 Q35966051-B2A4037F-61E2-4DEB-9243-5D18F9104126 Q36056222-D55A18B7-429C-4B0C-936D-E9D94A92040A Q36219834-8EDECFDA-0285-45C7-ADC1-411FD8BBDBA9 Q36283014-224E0439-B483-4697-9B9D-CD13AE18C2A3 Q36307893-1BB78339-066D-457B-9565-81F8DE58349E Q36338313-1FDBE78C-C245-4DF9-8849-53C4620FF47D Q36428471-12D58A4A-B617-4535-9315-88E4D3F7BB7B Q36428481-39D0F694-8B30-4574-A681-E29228AC55A3 Q36432096-34E81201-E0ED-4D44-9330-71C23D316167 Q36541100-F4536CC5-0610-4F23-9BDF-E52054DB9D05 Q36566857-C60FA0A4-E7F9-4590-96A8-FD6720858FD0 Q36698662-96AEC84D-8147-46A3-9062-F87FBC871F1E Q36789948-1D4F0176-8C5B-4979-B308-DE04EB6F06AF Q36997656-63DF1A05-89C3-4B46-9AA2-10D6FF633598 Q37017434-C7C5F10B-8FF2-4DDE-9A63-ACE6B0B029FD Q37187453-7853B84A-2387-4479-B399-63F2CD0C5D0D Q37230811-2573738B-BC66-4CF3-8D26-B8322EE1F283 Q37266543-042D551F-609B-4D27-8EAF-83BC4E8DD28D Q37589167-A1C6B7C6-268C-479A-A76A-4C45C32B7E76 Q37836943-3ED43166-2F29-4563-9F30-E729CC54D714 Q37946313-EF0604D0-A79A-4879-8564-188AB367BF05

P2860

Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.

http://www.wikidata.org/entity/Q34950386

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@ast

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@en

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@nl

type

label

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@ast

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@en

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@nl

prefLabel

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@ast

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@en

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@nl

P1433

Q34950386-709ED8A8-C87F-4856-8485-307C4F007D53

P1476

Q34950386-EACCE7FC-F7A3-4903-B6AB-3777488DC986

P2093

Q34950386-0C321435-9532-413B-AF14-096DC64B3F89

Q34950386-1279419A-4A4E-47CD-B721-C11B381EF7D0

Q34950386-7FDBAEF6-2AC9-4C65-A587-F1DA517755D4

Q34950386-C8DFF2BA-0EC8-414B-A911-59A59C48BA82

P2860

Q34950386-125E3EB3-D692-4F0F-A249-A315BC159F0B

Q34950386-15C63CDB-99E7-4C29-98B9-00B70973B877

Q34950386-203D8ED5-DF60-44F1-8A00-920FA57839EA

Q34950386-358AC597-6C51-4F57-9665-7B18CBFABD1B

Q34950386-3B9EF0FA-3D84-44A3-8DF7-DF870264C850

Q34950386-5875B9BF-525D-47F8-826B-A980AC3829BE

Q34950386-63AF4180-F050-45CA-9963-BA646159CE35

Q34950386-8609D695-5ABE-45AD-85DE-824BAA95C0A7

Q34950386-8CB17576-BD82-4F82-ADE1-D1348DC03996

Q34950386-B0B563A1-42AB-466D-9757-8E41DB5153D1

P304

Q34950386-9BECA38D-0757-4376-B717-311B00CC7821

P31

Q34950386-AD99FEC4-9AC5-449C-97E9-FFCDAC7E7DE2

P356

Q34950386-4061F9FA-1AD1-4B2D-8EDC-3DA219D77102

P407

Q34950386-1CB3A7F3-451E-461A-A15E-BCDB01C1518F

P433

Q34950386-D585834F-2FEF-4743-B118-3CB640EB43DA

P478

Q34950386-671E37FD-3353-4375-A661-D81D9EEB5F46

P577

Q34950386-BD5F952C-40F3-4908-8802-B5CF889AB7FD

P5875

Q34950386-F9D8E267-60BA-4FE4-85B5-B5BE115EBC18

P698

Q34950386-81FBB9FD-519D-48D7-B47B-A0D1897B5C01

P921

Q34950386-6C200B2F-EAAB-4DC9-AF9B-1CEDDF6BE7DF

P932

Q34950386-A9C641C3-FD79-4352-814C-F689FAA16DD2

P356

BMJ.326.7394.841

P1433

P1476

Effectiveness of anticholinerg ...... ve bladder: systematic review.

@en

P2093

Gaye Ellis

http://www.w3.org/2001/XMLSchema#string

Jean Hay-Smith

http://www.w3.org/2001/XMLSchema#string

Kate Moore

http://www.w3.org/2001/XMLSchema#string

Peter Herbison

http://www.w3.org/2001/XMLSchema#string

P2860

Urinary, faecal and sexual dysfunction in patients with multiple sclerosis

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

Meta-analyses involving cross-over trials: methodological issues

What are pragmatic trials?

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.

The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age.

The association between funding by commercial interests and study outcome in randomized controlled drug trials.

Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/Progestin Replacement Study (HERS) Research Group.

The patient with an overactive bladder--symptoms and quality-of-life issues.

Beyond conflict of interest. Transparency is the key

P304

841-844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.326.7394.841

http://www.w3.org/2001/XMLSchema#string

P407

P433

7394

http://www.w3.org/2001/XMLSchema#string

P478

326

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10797610

http://www.w3.org/2001/XMLSchema#string

P698

12702614

http://www.w3.org/2001/XMLSchema#string

P921

P932

153465

http://www.w3.org/2001/XMLSchema#string